RNS Number: 2733S Hutchmed (China) Limited 08 March 2023

Director's Share Dealing

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 8, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdac/AIM: HCM; SEHK:13) has received notifications that Mr Johnny Cheng, Executive Director and Chief Financial Officer, sold a total of 1,300,000 Ordinary Shares of US\$0.10 each of the Company at an average price of HK\$27.073 per Ordinary Shares on March 3, 2023 and March 6, 2023.

Following the above sale of 1,300,000 Ordinary Shares, the holding of Mr Cheng is 1,261,460 Ordinary Shares and 274,493 ADSs Note, representing approximately 0.3% of the current issued share capital of the Company.

Note: 274,493 ADSs included (i) 41,552 ADSs currently held by Mr Cheng, (ii) 217,800 ADSs granted under Share Option Scheme and (iii) 15,141 ADSs as beneficiary of a trust under long term incentive plan.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

| 1 | Details of the person discharging managerial responsibilities/person closely associated | | |
|----|---|---|--|
| a) | Name | Mr Johnny Cheng | |
| 2 | Reason for the notification | | |
| a) | Position/status | Executive Director and Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) | Name | HUTCHMED (China) Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US\$0.10 each DI ISIN: KYG4672N1198 | |
| b) | Nature of the transaction | Sale of 830,000 Ordinary Shares on March 3, 2023 at an average price of HK\$27.101. | |
| c) | Price(s) and volume(s) | Price(s) Volume(s) HK\$26.850 50,000 Ordinary Shares HK\$26.950 20,000 Ordinary Shares HK\$27.000 110,000 Ordinary Shares HK\$27.005 50,000 Ordinary Shares HK\$27.015 20,000 Ordinary Shares HK\$27.016 40,000 Ordinary Shares HK\$27.027 30,000 Ordinary Shares HK\$27.050 10,000 Ordinary Shares HK\$27.091 200,000 Ordinary Shares HK\$27.100 50,000 Ordinary Shares HK\$27.113 100,000 Ordinary Shares HK\$27.150 20,000 Ordinary Shares HK\$27.300 40,000 Ordinary Shares HK\$27.300 40,000 Ordinary Shares HK\$27.450 10,000 Ordinary Shares HK\$27.500 20,000 Ordinary Shares HK\$27.656 20,000 Ordinary Shares | |

| | | HK\$27.700 10,000 Ordinary Shares | |
|----|---|--|--|
| d) | Aggregated information - Aggregated volume - Price | Aggregated volume: 830,000 Ordinary Shares Price information: HK\$22,494,120 | |
| e) | Date of the transaction | 2023-03-03 | |
| f) | Place of the transaction | Hong Kong Stock Exchange | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US\$0.10 each DI ISIN: KYG4672N1198 | |
| b) | Nature of the transaction | Sale of 470,000 Ordinary Shares on March 6, 2023 at an average price of HK\$27.022. | |
| c) | Price(s) and volume(s) | Price(s) Volume(s) HK\$26.850 30,000 Ordinary Shares HK\$26.900 10,000 Ordinary Shares HK\$26.908 10,000 Ordinary Shares HK\$26.950 70,000 Ordinary Shares HK\$27.000 50,000 Ordinary Shares HK\$27.050 68,500 Ordinary Shares HK\$27.060 200,000 Ordinary Shares HK\$27.100 20,000 Ordinary Shares HK\$27.250 10,000 Ordinary Shares HK\$27.300 1,500 Ordinary Shares | |
| d) | Aggregated information - Aggregated volume - Price | Aggregated volume: 470,000 Ordinary Shares Price information: HK\$12,700,455 | |
| e) | Date of the transaction | 2023-03-06 | |
| f) | Place of the transaction | Hong Kong Stock Exchange | |

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch.med.com or follow us on LinkedIn.

Contacts

Investor Enquiries

Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 306 4490

Media Enquiries

Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile) bmiles@soleburystrat.com

Europe - Ben Atwell / Alex Shaw, FTI +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

Consulting

+44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com

Asia - Zhou Yi, Brunswick +852 9783 6894 (Mobile)

HUTCHMED@brunswickgroup.com

Nominated Advisor Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHNKFBDOBKKDNK